Duration of antibiotic therapy in critically ill patients: a randomized controlled trial of a C-reactive protein-based protocol versus an evidence-based best practice strategy without biomarkers

• DOI: 10.21203/rs.2.24070/v1
• Publication Date: 2020-02-20T21:52:05Z
• Authors: Isabela Nasciment...; Rafael Carneiro; Rafael Bergo; Larissa Martins; Enrico Colosimo; Carolina Oliveira; Saulo Saturnino; Marcus Vinícius A...; Cecília Ravetti; Vandack Nobre
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

Abstract Background: The rational use of antibiotics is one the main strategies to limit development bacterial resistance . We therefore sought evaluate effectiveness a C reactive protein-based protocol in reducing antibiotic treatment time critically ill patients.Methods: A randomized, open-label, controlled clinical trial conducted two intensive care units university hospital Brazil. Critically infected adult patients were randomly allocated to: i) intervention receive guided by daily monitoring CRP levels, and ii) control according best practices for antibiotics.Results : 130 included (n=64) (n=66) groups. In intention treat analysis, median duration therapy index infectious episode was 7.0 (5.0-8.8) days (7.0-11.3) (p = 0.011) significant difference between groups identified curve cumulative suspension antibiotics, with less exposure group 0.007). per involving 59 each group, 6.0 (5.0-8.0) (7.0- 10.0) Conclusions: Daily levels may aid reduction patients, even scenario judicious antimicrobials. Trial Registry ClinicalTrials.gov Identifier: NCT02987790. Registered 09 December 2016, https://clinicaltrials.gov/ct2/show/NCT02987790